TY - JOUR
T1 - MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening
AU - Iehara, T.
AU - Hosoi, H.
AU - Akazawa, K.
AU - Matsumoto, Y.
AU - Yamamoto, K.
AU - Suita, S.
AU - Tajiri, T.
AU - Kusafuka, T.
AU - Hiyama, E.
AU - Kaneko, M.
AU - Sasaki, F.
AU - Sugimoto, T.
AU - Sawada, T.
N1 - Funding Information:
The authors gratefully thank many pediatric oncologists and pediatric surgeons in Japan for providing us the important clinical data of patients study. This study was supported in part by grants for cancer and mass-screening research from the Kyoto Prefectural Govement and the Children’s Cancer Association of Japan. This study was also supported in part by Grant-in-Aid for Scientific Research (16-Kodomo-012) from the Ministry of Health, Labour, and Welfare of the Government of Japan.
PY - 2006/5/22
Y1 - 2006/5/22
N2 - MYCN is the most powerful prognostic factor in cases of older children. However, how MYCN is related to the prognosis of infantile cases is not clear. A mass screening program was carried out by measuring urinary catecholamine metabolites (VMA and HVA) from 6-month-old infants. Of 2084 cases detected by the screening program, MYCN amplification (MNA) was examined by Southern blot analyses in 1533 cases from 1987 to 2000. Of the 1533 cases examined, 1500 (97.8%) showed no MNA, 20 cases (1.3%) showed MNA from three to nine copies, and 13 (0.8%) cases showed more than 10 copies. The 4-year overall survival rates of these three groups (99, 89 and 53%, respectively) were significantly different (P<0.001), indicating that MYCN copy number correlates with the prognosis. Cases with MNA more than 10 copies were more advanced than those without amplification (stage III, IV vs I, II, IVs; P<0.001). Patients with MNA more than 10 copies had significantly higher serum levels of neuron-specific-enolase (NSE) and ferritin than non-amplified patients (P = 0.049, P = 0.025, respectively). MYCN amplification was strongly correlated with a poor prognosis in infantile neuroblastoma cases. Therefore, for the selection of appropriate treatment, an accurate determination of MNA is indispensable.
AB - MYCN is the most powerful prognostic factor in cases of older children. However, how MYCN is related to the prognosis of infantile cases is not clear. A mass screening program was carried out by measuring urinary catecholamine metabolites (VMA and HVA) from 6-month-old infants. Of 2084 cases detected by the screening program, MYCN amplification (MNA) was examined by Southern blot analyses in 1533 cases from 1987 to 2000. Of the 1533 cases examined, 1500 (97.8%) showed no MNA, 20 cases (1.3%) showed MNA from three to nine copies, and 13 (0.8%) cases showed more than 10 copies. The 4-year overall survival rates of these three groups (99, 89 and 53%, respectively) were significantly different (P<0.001), indicating that MYCN copy number correlates with the prognosis. Cases with MNA more than 10 copies were more advanced than those without amplification (stage III, IV vs I, II, IVs; P<0.001). Patients with MNA more than 10 copies had significantly higher serum levels of neuron-specific-enolase (NSE) and ferritin than non-amplified patients (P = 0.049, P = 0.025, respectively). MYCN amplification was strongly correlated with a poor prognosis in infantile neuroblastoma cases. Therefore, for the selection of appropriate treatment, an accurate determination of MNA is indispensable.
UR - http://www.scopus.com/inward/record.url?scp=33646834444&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646834444&partnerID=8YFLogxK
U2 - 10.1038/sj.bjc.6603149
DO - 10.1038/sj.bjc.6603149
M3 - Article
C2 - 16670717
AN - SCOPUS:33646834444
SN - 0007-0920
VL - 94
SP - 1510
EP - 1515
JO - British journal of cancer
JF - British journal of cancer
IS - 10
ER -
